TY - JOUR
T1 - Cognitive performance in early, treatment-resistant psychosis patients
T2 - Could cognitive control play a role in persistent symptoms?
AU - Thomas, Megan
AU - Szentgyorgyi, Timea
AU - Vanes, Lucy D.
AU - Mouchlianitis, Elias
AU - Barry, Erica F.
AU - Patel, Krisna
AU - Wong, Katie
AU - Joyce, Dan
AU - Shergill, Sukhwinder
N1 - Funding Information:
This research was funded by a European Research Council Grant to SSS (grant number 311686 ), and developed by the National Institute for Health Research ( NIHR ) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London and a joint infrastructure grant from Guy's and St Thomas' Charity and the Maudsley Charity .
Publisher Copyright:
© 2020
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/1
Y1 - 2021/1
N2 - Approximately one third of psychosis patients fail to respond to conventional antipsychotic medication, which exerts its effect via striatal dopamine receptor antagonism. The present study aimed to investigate impaired cognitive control as a potential contributor to persistent positive symptoms in treatment resistant (TR) patients. 52 medicated First Episode Psychosis (FEP) patients (17 TR and 35 non-TR (NTR)) took part in a longitudinal study in which they performed a series of cognitive tasks and a clinical assessment at two timepoints, 12 months apart. Cognitive performance at baseline was compared to that of 39 healthy controls (HC). Across both timepoints, TR patients were significantly more impaired than NTR patients in a task of cognitive control, while performance on tasks of phonological and semantic fluency, working memory and general intelligence did not differ between patient groups. No significant associations were found between cognitive performance and psychotic symptomatology, and no significant performance changes were observed from the first to second timepoint in any of the cognitive tasks within patient groups. The results suggest that compared with NTR patients, TR patients have an exacerbated deficit specific to cognitive control, which is established early in psychotic illness and stabilises in the years following a first episode.
AB - Approximately one third of psychosis patients fail to respond to conventional antipsychotic medication, which exerts its effect via striatal dopamine receptor antagonism. The present study aimed to investigate impaired cognitive control as a potential contributor to persistent positive symptoms in treatment resistant (TR) patients. 52 medicated First Episode Psychosis (FEP) patients (17 TR and 35 non-TR (NTR)) took part in a longitudinal study in which they performed a series of cognitive tasks and a clinical assessment at two timepoints, 12 months apart. Cognitive performance at baseline was compared to that of 39 healthy controls (HC). Across both timepoints, TR patients were significantly more impaired than NTR patients in a task of cognitive control, while performance on tasks of phonological and semantic fluency, working memory and general intelligence did not differ between patient groups. No significant associations were found between cognitive performance and psychotic symptomatology, and no significant performance changes were observed from the first to second timepoint in any of the cognitive tasks within patient groups. The results suggest that compared with NTR patients, TR patients have an exacerbated deficit specific to cognitive control, which is established early in psychotic illness and stabilises in the years following a first episode.
KW - Cognitive control
KW - First episode psychosis
KW - Treatment response
UR - http://www.scopus.com/inward/record.url?scp=85097434291&partnerID=8YFLogxK
U2 - 10.1016/j.psychres.2020.113607
DO - 10.1016/j.psychres.2020.113607
M3 - Article
C2 - 33285345
AN - SCOPUS:85097434291
SN - 0165-1781
VL - 295
JO - Psychiatry Research
JF - Psychiatry Research
M1 - 113607
ER -
